Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BTCY Biotricity	$0.48 -3.0%	$0.44	$0.19 ▼ $0.83	$11.96M	1.12	38,444 shs	25,880 shs
CHEK Check-Cap	$0.64 -1.2%	$0.73	$0.56 ▼ $3.04	$3.77M	0.19	25,977 shs	2,612 shs
DRCT Direct Digital	$0.41 +3.6%	$0.53	$0.38 ▼ $6.59	$8.94M	6.04	762,633 shs	118,928 shs
SLGL Sol-Gel Technologies	$25.80 +40.2%	$10.68	$4.01 ▼ $26.89	$51.26M	1.21	22,397 shs	114,815 shs

10 Best Stocks to Own: Fall 2025

Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Fall 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BTCY Biotricity	-10.00%	-8.33%	+3.13%	-4.81%	+3.13%
CHEK Check-Cap	-1.68%	-5.15%	-14.59%	-24.42%	-66.28%
DRCT Direct Digital	+1.04%	-13.47%	-24.33%	-11.93%	-87.89%
SLGL Sol-Gel Technologies	+3.72%	+19.09%	+118.53%	+139.43%	+309.80%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
BTCY Biotricity	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
CHEK Check-Cap	0.403 of 5 stars	0.0	3.0	0.0	0.0	1.7	0.0	0.6
DRCT Direct Digital	2.511 of 5 stars	3.3	3.0	0.0	0.0	1.3	2.5	0.6
SLGL Sol-Gel Technologies	1.0593 of 5 stars	0.0	3.0	0.0	0.0	4.0	1.7	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BTCY Biotricity	2.00	Hold	N/A	N/A
CHEK Check-Cap	0.00	N/A	N/A	N/A
DRCT Direct Digital	2.50	Moderate Buy	$6.00	1,359.14% Upside
SLGL Sol-Gel Technologies	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest CHEK, DRCT, SLGL, and BTCY Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target	Details
8/8/2025	DRCT Direct Digital	Zacks Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold

(Data available from 8/21/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BTCY Biotricity	$12.06M	0.99	N/A	N/A	($1.30) per share	-0.37
CHEK Check-Cap	N/A	N/A	N/A	N/A	$4.05 per share	N/A
DRCT Direct Digital	$62.29M	0.15	N/A	N/A	($1.09) per share	-0.38
SLGL Sol-Gel Technologies	$11.54M	6.24	N/A	N/A	$11.44 per share	2.26

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BTCY Biotricity	-$14.09M	-$0.21	N/A	∞	N/A	-80.42%	N/A	-188.47%	N/A
CHEK Check-Cap	-$17.57M	-$3.00	N/A	∞	N/A	N/A	N/A	N/A	N/A
DRCT Direct Digital	-$6.24M	-$1.83	N/A	N/A	N/A	-25.99%	N/A	-36.29%	N/A
SLGL Sol-Gel Technologies	-$10.58M	-$1.23	N/A	N/A	N/A	-14.25%	-11.80%	-9.39%	N/A

Latest CHEK, DRCT, SLGL, and BTCY Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/15/2025	Q2 2025	SLGL Sol-Gel Technologies	-$0.67	$4.17	+$4.84	$4.17	$2.86 million	$17.26 million
8/5/2025	Q2 2025	DRCT Direct Digital	-$0.96	-$0.23	+$0.73	-$0.23	$11.84 million	$10.14 million
5/23/2025	Q1 2025	SLGL Sol-Gel Technologies	N/A	-$3.20	N/A	-$3.20	N/A	$1.03 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
BTCY Biotricity	N/A	N/A	N/A	N/A	N/A
CHEK Check-Cap	N/A	N/A	N/A	N/A	N/A
DRCT Direct Digital	N/A	N/A	N/A	N/A	N/A
SLGL Sol-Gel Technologies	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BTCY Biotricity	N/A	0.23	0.10
CHEK Check-Cap	N/A	N/A	N/A
DRCT Direct Digital	N/A	0.49	0.49
SLGL Sol-Gel Technologies	N/A	7.32	5.12

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BTCY Biotricity	3.89%
CHEK Check-Cap	1.07%
DRCT Direct Digital	4.02%
SLGL Sol-Gel Technologies	26.18%

Insider Ownership

Company	Insider Ownership
BTCY Biotricity	10.10%
CHEK Check-Cap	0.48%
DRCT Direct Digital	62.82%
SLGL Sol-Gel Technologies	66.51%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BTCY Biotricity	40	24.91 million	22.08 million	Optionable
CHEK Check-Cap	80	5.85 million	5.82 million	Not Optionable
DRCT Direct Digital	60	22.52 million	8.37 million	Not Optionable
SLGL Sol-Gel Technologies	50	2.79 million	933,000	Optionable

CHEK, DRCT, SLGL, and BTCY Headlines

Recent News About These Companies

Sol-Gel Stock Delivers Over 150% Gain - Can The Upcoming Q4 Clinical Data Readout Sustain The Rally?

August 21 at 5:50 AM | rttnews.com

Sol-Gel Technologies Reports Strong Q2 2025 Results

August 20 at 4:20 AM | msn.com

Sol-Gel Technologies (NASDAQ:SLGL) Trading Up 4.3% on Better-Than-Expected Earnings

August 20 at 2:35 AM | americanbankingnews.com

Sol-Gel Reports Second Quarter 2025 Financial Results and Provides Corporate Updates

August 15, 2025 | globenewswire.com

Sol-Gel Technologies Ltd. (SLGL) Stock Price Today - WSJ

July 25, 2025 | wsj.com

Sol-Gel Technologies Ltd. (SLGL) - Yahoo Finance

July 9, 2025 | finance.yahoo.com

SLGL Sol-Gel Technologies Ltd. - Seeking Alpha

June 26, 2025 | seekingalpha.com

Sol-Gel Technologies Ltd

June 21, 2025 | morningstar.comM

Sol Gel Tech Stock Price History

June 1, 2025 | investing.com

Sol-Gel Technologies Ltd.: Sol-Gel Reports First Quarter 2025 Results

May 23, 2025 | finanznachrichten.de

Sol-Gel Stock Tumbles Over Underwhelming Q1 Earnings: Retail Stays Pessimistic

May 23, 2025 | msn.com

Sol-Gel Technologies Reports Q1 2025 Financial Results and Increased R&D Expenses

May 23, 2025 | quiverquant.comQ

Sol-Gel Reports First Quarter 2025 Results

May 23, 2025 | globenewswire.com

Insider Buying: Sol-Gel Technologies CEO & Executive Chairman Bought US$98k Of Shares

May 3, 2025 | uk.finance.yahoo.com

This Sol-Gel Technologies Insider Increased Their Holding In The Last Year

May 2, 2025 | finance.yahoo.com

Sol-Gel Announces Reverse Share Split

May 1, 2025 | globenewswire.com

Sol-Gel, Mayne Pharma enter product purchase agreement

April 17, 2025 | markets.businessinsider.com

Sol-Gel Technologies Ltd.: Sol-Gel and Mayne Pharma Announce the Purchase of EPSOLAY and TWYNEO in the U.S.

April 17, 2025 | finanznachrichten.de

Sol-Gel and Mayne Pharma Announce the Purchase of EPSOLAY® and TWYNEO® in the U.S.

April 17, 2025 | globenewswire.com

Global Sol-Gel Coatings Market Research 2025-2035: Competitive Landscape, Functional Properties and Applications, End-users, Technology Fundamentals, Overview and Growth Analysis

April 7, 2025 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

CHEK, DRCT, SLGL, and BTCY Company Descriptions

Biotricity NASDAQ:BTCY

$0.48 -0.02 (-3.03%)

As of 03:38 PM Eastern

Biotricity, Inc., a medical technology company, provides biometric data monitoring solutions in the United States. The company focuses on delivery of remote monitoring solutions to medical, healthcare, and consumer markets, including diagnostic and post-diagnostic solutions for lifestyle and chronic illnesses. It offers Bioflux mobile cardiac telemetry solution, an integrated ECG device; and ECG analysis software that analyzes and synthesizes patient ECG monitoring data, as well as software components. The company is based in Redwood City, California.

Check-Cap NASDAQ:CHEK

$0.64 -0.01 (-1.24%)

Closing price 03:41 PM Eastern

Extended Trading

$0.64 0.00 (0.00%)

As of 06:10 PM Eastern

Check-Cap Ltd., a clinical stage medical diagnostics company, engages in the development of a capsule-based screening technology that utilizes ultra-low-dose X-rays to scan the inner lining of the colon for precancerous polyps, and other structural abnormalities in Israel. Its C-Scan system consists of C-Scan Cap, an X-ray scanning capsule for detection of suspected polyps; C-Scan Track, a disposable system attached to the patient's back through biocompatible adhesive skin patches; and C-Scan View software, a client/server-based application that enables procedure data download from the C-Scan Track, data analysis, and report generation. Check-Cap Ltd. was incorporated in 2004 and is based in Isfiya, Israel.

Direct Digital NASDAQ:DRCT

$0.41 +0.01 (+3.55%)

Closing price 04:00 PM Eastern

Extended Trading

$0.42 +0.00 (+0.92%)

As of 07:27 PM Eastern

Direct Digital Holdings, Inc. operates as an end-to-end full-service programmatic advertising platform. The company's platform primarily focuses on providing advertising technology, data-driven campaign optimization, and other solutions to underserved and less efficient markets on both the buy- and sell-side of the digital advertising ecosystem. It serves various industry verticals, such as travel, healthcare, education, financial services, consumer products, and other sectors with a focus on small and mid-sized businesses. The company was founded in 2018 and is headquartered in Houston, Texas.

Sol-Gel Technologies NASDAQ:SLGL

$25.80 +7.40 (+40.22%)

Closing price 04:00 PM Eastern

Extended Trading

$25.10 -0.70 (-2.69%)

As of 07:55 PM Eastern

Sol-Gel Technologies Ltd., together with its subsidiary Sol-Gel Technologies Inc., develops topical dermatological drugs for patients with severe skin conditions in Israel. The company offers Twyneo, a once-daily, non-antibiotic topical cream for the treatment of acne vulgaris; and Epsolay, a once-daily topical cream for the treatment of papulopustular (subtype II) rosacea. It also develops SGT-610 that is in Phase 3 clinical trials for the treatment of Gorlin Syndrome; and SGT-210, which has completed Phase I clinical trial, to treat rare hyperkeratinization disorders, such as Darier, PC, PPK, Olmsted, etc. In addition, the company is also involved in the development of generic topical dermatological drug products. It has collaboration with Padagis Israel Pharmaceuticals Ltd; and license agreements with Galderma Holding SA and Searchlight Pharma Inc. Sol-Gel Technologies Ltd. was incorporated in 1997 and is headquartered in Ness Ziona, Israel.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time